||EPS - Basic
||Market Cap (m)
|Equity Investment Instruments
|Biotech Growth Daily Update: Biotech Gwth is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker BIOG. The last closing price for Biotech Growth was 696.50p.|
Biotech Gwth has a 4 week average price of 712.23p and a 12 week average price of 708.40p.
The 1 year high share price is 748p while the 1 year low share price is currently 520p.
There are currently 60,351,754 shares in issue and the average daily traded volume is 93,250 shares. The market capitalisation of Biotech Gwth is £419,142,931.53.
|philo124: Just read their Report and Accounts; not sure I should have sold even at these levels- looks like the story and share price has further to go in 2015.|
|urgentclick: Looks good to me: downside recently around 409p (I picked up 1000 at that price point) and upside 550p not long ago. And the NAV comfortably exceeding the share price.|
|yiyack3: In my experience many AIM companies are pretty well worthless, run by a CEO and a crony or two who like the good life, first class on expenses, get rich as quick as poss and don't worry when the company runs out of cash, goes bust and all the shareholders lose their investments. If an AIM company gets to be popular on the ADVFN and other bulletin boards, do what you can to hitch a ride on rising share price, then take profits and get out. Don't ever believe the story behind an AIM market share|
|northernlass: THE QUARTER'S BEST PERFORMER
Looking at individual investment portfolios, the Biotech Growth trust was the quarter's best performer in terms of both net asset value (NAV) and share price. Over the three months, its NAV rose 19.1% while share price was up 11.4% on a total return basis.
|chingman: Latest from Edison -
The Biotech Growth Trust Plc (BIOG) has put in a respectable performance during the past 12 months, outperforming its benchmark, the NASDAQ Biotechnology Index (sterling adjusted), by 2.8% in terms of NAV total return and 3.9% in terms of share price total return. The manager believes that concerns over US healthcare reform were overdone and, while this cloud of uncertainty has lifted, concerns regarding the outlook in Europe have delayed the reversion. Looking forward, the manager considers that; biotech will be a net beneficiary of healthcare reform; the regulatory environment will continue to improve; M|
|damanko: Ian - two is a crowd ...............
I didn't bother participating in the recent fund raising, as the amount payable (ie the stated NAV) was some way north of the share price. In fact, I meant to write to the board, and ask who on earth would bother (amongst longer term holders) - when this was the case. Whatever, the institutions were keen, and the price has carried on its mild upward trend.
Worth tucking away. Mind you, having bought about nine years ago, I'm now only 25% or so down on what I paid. Ho hum....|
Biotech Growth share price data is direct from the London Stock Exchange